Merck has had a very busy week -- and investment dollars have followed.
BioDelivery Sciences International, Chiasma Inc. and TherapeticsMD all feature promising treatments.
Amgen is finally making an expected splash out of its cash pile, but questions are abounding about the cost paid for Celgene's Otezla.
Stemline Therapeutics and Flexion Therapeutics both saw their shares climb on positive news developments.
Jounce Therapeutics and Ocular Therapeutix each provided investors with positive news morsels last week.
Pfizer will combine its off-patent drug business with Mylan in the as-yet-to-be-named new company.
Investors should keep tabs on these "focus events" from this quartet of U.S.-listed Japanese drugmakers that can make or break their treatments.
Intra-Cellular Therapies and Acadia Pharmaceuticals are worth investors' attention.
The initial public offering of Hansoh Pharmaceutical Group made the Chinese couple Zhong Huijuan and Sun Piaoyang the richest in the nation.
I want you to remember Eli Lilly and Johnson & Johnson the next time you are about to dump a stock because of some bits of bad news.